BioCentury
ARTICLE | Clinical News

Bristol-Myers discontinues Alzheimer's compound avagacestat

December 4, 2012 3:41 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) discontinued development of avagacestat ( BMS-708163) after data from Phase II trials evaluating the product for mild to moderate Alzheimer's disease and predementia AD did not "establish a profile that supported advancement" to Phase III testing. The pharma said it plans to present data from the predementia trial next year. ...